CN110678178B - Mk2抑制剂的形式和组合物 - Google Patents

Mk2抑制剂的形式和组合物 Download PDF

Info

Publication number
CN110678178B
CN110678178B CN201880032086.2A CN201880032086A CN110678178B CN 110678178 B CN110678178 B CN 110678178B CN 201880032086 A CN201880032086 A CN 201880032086A CN 110678178 B CN110678178 B CN 110678178B
Authority
CN
China
Prior art keywords
compound
disorder
disease
syndrome
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201880032086.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN110678178A (zh
Inventor
J·韩
L·黄
U·杰恩
Y·李
J·马罗那
K·莫尔特
C·帕巴
A·L·卢切尔曼
J·徐
D·邹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Celgene Avilomics Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Celgene Avilomics Research Inc filed Critical Bristol Myers Squibb Co
Publication of CN110678178A publication Critical patent/CN110678178A/zh
Application granted granted Critical
Publication of CN110678178B publication Critical patent/CN110678178B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Cosmetics (AREA)
CN201880032086.2A 2017-03-16 2018-03-15 Mk2抑制剂的形式和组合物 Expired - Fee Related CN110678178B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472015P 2017-03-16 2017-03-16
US62/472,015 2017-03-16
PCT/US2018/022543 WO2018170199A1 (en) 2017-03-16 2018-03-15 Forms and compositions of a mk2 inhibitor

Publications (2)

Publication Number Publication Date
CN110678178A CN110678178A (zh) 2020-01-10
CN110678178B true CN110678178B (zh) 2023-10-03

Family

ID=63522534

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880032086.2A Expired - Fee Related CN110678178B (zh) 2017-03-16 2018-03-15 Mk2抑制剂的形式和组合物

Country Status (8)

Country Link
US (2) US10882867B2 (https=)
EP (1) EP3595658A4 (https=)
JP (2) JP2020514360A (https=)
CN (1) CN110678178B (https=)
AU (1) AU2018236286B2 (https=)
CA (1) CA3054823A1 (https=)
MX (1) MX393600B (https=)
WO (1) WO2018170199A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
US11230551B2 (en) 2017-03-16 2022-01-25 Celgene Car Llc Deuterated analogs of MK2 inhibitors and uses thereof
JP7282039B2 (ja) 2017-03-16 2023-05-26 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤、その合成、およびそれに至るまでの中間体
JP7200120B2 (ja) 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
WO2018170204A1 (en) * 2017-03-16 2018-09-20 Celgene Car Llc 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
CN114364681A (zh) * 2019-05-17 2022-04-15 西建卡尔有限责任公司 治疗mk2介导的病症的方法
KR20230142529A (ko) 2021-02-01 2023-10-11 셀진 코포레이션 Mk2 억제제, 이의 합성, 및 이의 중간체
MX2024008704A (es) 2022-01-14 2024-07-22 Shanghai Hansoh Biomedical Co Ltd Derivado policiclico que contiene piridina, y metodo de preparacion de este y uso de este.

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038705A1 (en) * 1996-04-12 1997-10-23 Bristol-Myers Squibb Company N-formyl hydroxylamine containing compounds useful as ace inhibitors and/or nep inhibitors
CN101360750A (zh) * 2005-11-23 2009-02-04 英特芒尼公司 应激活化蛋白激酶系统的调节方法
CN102464639A (zh) * 2010-11-16 2012-05-23 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN102753179A (zh) * 2009-11-17 2012-10-24 密执安大学评议会 具有治疗性能的1,4-苯并二氮杂*-2,5-二酮和相关化合物
CN103717597A (zh) * 2011-04-21 2014-04-09 原真股份有限公司 作为激酶抑制剂的杂环化合物
CN105163738A (zh) * 2013-03-15 2015-12-16 西建阿维拉米斯研究公司 Mk2抑制剂和其用途
WO2016032882A1 (en) * 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
WO2016044463A2 (en) * 2014-09-17 2016-03-24 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1747949A (zh) * 2002-12-20 2006-03-15 法马西亚公司 无环吡唑化合物
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
US7790712B2 (en) * 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
CN101687869A (zh) 2007-07-16 2010-03-31 诺瓦提斯公司 作为mk2抑制剂的四环内酰胺衍生物
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
HK1210696A1 (en) 2012-07-11 2016-05-06 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US9695193B2 (en) * 2013-06-26 2017-07-04 The Trustees Of Columbia University In The City Of New York Inhibitors of Plasmodium falciparum equilibrative nucleoside transporter type I as anti-parasitic compounds
WO2016112292A1 (en) 2015-01-08 2016-07-14 Moerae Matrix, Inc. Formulation of mk2 inhibitor peptides
JP7282039B2 (ja) 2017-03-16 2023-05-26 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤、その合成、およびそれに至るまでの中間体
WO2018170204A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof
US11230551B2 (en) 2017-03-16 2022-01-25 Celgene Car Llc Deuterated analogs of MK2 inhibitors and uses thereof
JP7200120B2 (ja) 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
CN114364681A (zh) 2019-05-17 2022-04-15 西建卡尔有限责任公司 治疗mk2介导的病症的方法
US20230255979A1 (en) 2020-07-24 2023-08-17 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
KR20230142529A (ko) 2021-02-01 2023-10-11 셀진 코포레이션 Mk2 억제제, 이의 합성, 및 이의 중간체

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038705A1 (en) * 1996-04-12 1997-10-23 Bristol-Myers Squibb Company N-formyl hydroxylamine containing compounds useful as ace inhibitors and/or nep inhibitors
CN101360750A (zh) * 2005-11-23 2009-02-04 英特芒尼公司 应激活化蛋白激酶系统的调节方法
CN102753179A (zh) * 2009-11-17 2012-10-24 密执安大学评议会 具有治疗性能的1,4-苯并二氮杂*-2,5-二酮和相关化合物
CN102464639A (zh) * 2010-11-16 2012-05-23 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN103717597A (zh) * 2011-04-21 2014-04-09 原真股份有限公司 作为激酶抑制剂的杂环化合物
CN105163738A (zh) * 2013-03-15 2015-12-16 西建阿维拉米斯研究公司 Mk2抑制剂和其用途
WO2016032882A1 (en) * 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
WO2016044463A2 (en) * 2014-09-17 2016-03-24 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
吕扬等."晶型药物".《晶型药物》.人民卫生出版社,2009,第6、24-25、138页. *

Also Published As

Publication number Publication date
JP2020514360A (ja) 2020-05-21
WO2018170199A1 (en) 2018-09-20
CN110678178A (zh) 2020-01-10
US11629153B2 (en) 2023-04-18
CA3054823A1 (en) 2018-09-20
EP3595658A1 (en) 2020-01-22
EP3595658A4 (en) 2020-11-25
AU2018236286B2 (en) 2022-02-17
US10882867B2 (en) 2021-01-05
US20210198276A1 (en) 2021-07-01
US20200148701A1 (en) 2020-05-14
MX2019010643A (es) 2019-10-17
AU2018236286A1 (en) 2019-09-19
JP2023017840A (ja) 2023-02-07
MX393600B (es) 2025-03-24

Similar Documents

Publication Publication Date Title
CN110678178B (zh) Mk2抑制剂的形式和组合物
CN109071489B (zh) 吲唑的合成
CA2963581C (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
JP2023051962A (ja) ９，１０，１１，１２－テトラヒドロ－８ｈ－［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２－ｆ］キノリン－８－オン化合物およびその使用
RS59669B1 (sr) Kristalni oblik bisulfatnog inhibitora jak kinaze i postupak njegovog dobijanja
CN110461847A (zh) (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
AU2018236290A1 (en) MK2 inhibitors, synthesis thereof, and intermediates thereto
US20090076272A1 (en) Polymorphs of eszopiclone malate
CA3101438A1 (en) Small molecule inhibitors of the jak family of kinases
JP2025538371A (ja) 含窒素複素環系化合物の薬用可能な塩、結晶型及び調製方法
JP2014510122A (ja) ｍＴＯＲ阻害剤としてのジヒドロピロロピリミジン誘導体
IL323224A (en) Crystalline form
CN109721531B (zh) 一种新型的脂质体激酶抑制剂
EP4134369B1 (en) Solid forms of tetrahydropyranyl amino-pyrrolopyrimidinone compounds
JP2023502675A (ja) 核タンパク質阻害剤の結晶形及びその使用
US20240352040A1 (en) Crystal form of ripk1 inhibitor, acid salt thereof, and crystal form of acid salt thereof
US11261182B2 (en) Crystal of pyrido[3,4-d]pyrimidine derivative or solvate thereof
JP2024520920A (ja) イミダゾリジノン類化合物の多形体、調製方法及びその使用
KR20160143842A (ko) 치환된 이미다조피리디닐-아미노피리딘 화합물의 염 및 다형체
EP3098220A1 (en) Process for the preparation of a nadph oxidase inhibitor and its polymorphs and uses thereof
WO2025242167A1 (zh) Pkmyt1抑制剂的多晶型、其制备方法及其应用
TW202602874A (zh) Akt1抑制劑及其鹽之固態形式
EP4714947A1 (en) Crystal form of pyrimido azacyclo compound, and preparation method therefor and use thereof
CN121773096A (zh) 4-氯-5-[4-(2,6-二氯苯基)磺酰基哌嗪-1-基]-1-苯并呋喃-2-甲酸的l-赖氨酸盐及其各种形式
CN121270516A (zh) 一种irak抑制剂化合物的晶型及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230625

Address after: new jersey

Applicant after: BRISTOL-MYERS SQUIBB Co.

Address before: Bermuda Hamilton

Applicant before: CELGENE AVILOMICS RESEARCH, Inc.

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20231003